title: Methylation profile of triple-negative breast carcinomas.
abstract: Breast cancer is a group of clinically, histopathologically and molecularly heterogeneous diseases, with different outcomes and responses to treatment. Triple-negative (TN) breast cancers are defined as tumors that lack the expression of estrogen receptor, progesterone receptor and epidermal growth factor receptor 2. This subgroup accounts for 15% of all types of breast cancer and its prevalence is higher among young African, African-American and Latino women. The hypermethylation of CpG islands (CpGI) is a common epigenetic alteration for suppressing gene expression in breast cancer and has been shown to be a key factor in breast carcinogenesis. In this study we analyzed the hypermethylation of 110 CpGI within 69 cancer-related genes in TN tumors. For the methylation analysis, we used the methyl-specific multiplex-ligation probe amplification assay. We found that the number of methylated CpGI is similar between TN and non-TN tumors, but the methylated genes between the groups are different. The methylation profile of TN tumors is defined by the methylation of five genes (that is, CDKN2B, CD44, MGMT, RB and p73) plus the non-methylation of 11 genes (that is, GSTP1, PMS2, MSH2, MLH1, MSH3, MSH6, DLC1, CACNA1A, CACNA1G, TWIST1 and ID4). We conclude that TN tumors have a specific methylation profile. Our findings give new information for better understanding tumor etiology and encourage future studies on potential drug targets for triple-negative breast tumors, which now lack a specific treatment.
authors.affiliation: 1] Laboratory of Cellular and Molecular Biology, IHEM-CCT-CONICET, School of Medical Sciences, National University of Cuyo, Mendoza, Argentina [2] School of Medical Sciences, National University of Cuyo, Mendoza, Argentina.
authors.forename: M T
authors.initials: MT
authors.lastname: Branham
authors.forename: D M
authors.initials: DM
authors.lastname: Marzese
authors.forename: S R
authors.initials: SR
authors.lastname: Laurito
authors.forename: F E
authors.initials: FE
authors.lastname: Gago
authors.forename: J I
authors.initials: JI
authors.lastname: Orozco
authors.forename: O M
authors.initials: OM
authors.lastname: Tello
authors.forename: L M
authors.initials: LM
authors.lastname: Vargas-Roig
authors.forename: M
authors.initials: M
authors.lastname: Roqué
references.citation: Semin Cancer Biol. 2009 Jun;19(3):165-71
references.pmid: 19429480
references.citation: Nucleic Acids Res. 2005 Aug 16;33(14):e128
references.pmid: 16106041
references.citation: Breast Cancer Res. 2007;9(5):R65
references.pmid: 17910759
references.citation: Nat Rev Clin Oncol. 2010 Dec;7(12):683-92
references.pmid: 20877296
references.citation: Breast Cancer Res. 2010;12(5):R68
references.pmid: 20813035
references.citation: Genome Res. 2009 Sep;19(9):1639-45
references.pmid: 19541911
references.citation: Clin Cancer Res. 2008 Dec 15;14(24):8010-8
references.pmid: 19088017
references.citation: Mol Cell Probes. 2010 Oct;24(5):271-80
references.pmid: 20561583
references.citation: Oncogene. 2007 Mar 29;26(14):2126-32
references.pmid: 17016441
references.citation: Cancer. 2007 Jan 1;109(1):25-32
references.pmid: 17146782
references.citation: Br J Cancer. 2010 Jul 13;103(2):249-55
references.pmid: 20551954
references.citation: Curr Oncol. 2011 Aug;18(4):e173-9
references.pmid: 21874107
references.citation: Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):661-7
references.pmid: 22414280
references.citation: Oncologist. 2011;16 Suppl 1:71-8
references.pmid: 21278443
references.citation: Breast Cancer Res. 2010;12 Suppl 2:S3
references.pmid: 21050424
references.citation: Breast Cancer Res Treat. 2005 May;91(2):179-86
references.pmid: 15868446
references.citation: Biochim Biophys Acta. 2009 Dec;1796(2):162-75
references.pmid: 19527773
references.citation: Nucleic Acids Res. 2002 Jun 15;30(12):e57
references.pmid: 12060695
references.citation: N Engl J Med. 2005 Mar 10;352(10):997-1003
references.pmid: 15758010
references.citation: N Engl J Med. 2008 Mar 13;358(11):1148-59
references.pmid: 18337604
references.citation: Clin Cancer Res. 2010 Nov 1;16(21):5107-13
references.pmid: 20823149
references.citation: Breast Cancer Res Treat. 2012 Jul;134(1):131-7
references.pmid: 22228432